New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
06:04 EDTBRK.A, HNZM&A volume grows worldwide, Reuters reports
In Q1, global deal volume jumped 6% to $430.4B through March 19, even though Europe and the Asia-Pacific region declined 31% and 10%, respectively, according to Thomson Reuters data. U.S. deal activity surged 62% during the quarter, thanks to a number of deals valued at over $5B, including the $23.2B takeover of H..J. Heinz Co (HNZ) by Berkshire Hathaway (BRK.A) and Brazilian private equity firm 3G Capital. Reference Link
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
September 24, 2015
17:04 EDTAMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use